title: Elevated expression of MGb2-Ag/TRAK1 is correlated with poor prognosis in patients with colorectal cancer.
abstract: OBJECTIVE
  MGb2, a mouse-derived monoclonal antibody specific to gastric carcinoma, was developed in our laboratory. Nevertheless, the potential role of MGb2-antigen/TRAK1 (MGb2-Ag/TRAK1) in colorectal cancer (CRC) is unclear. The aim of this study was to investigate the relationship between MGb2-Ag/TRAK1 expression and the clinicopathological characteristics of CRC. The potential utility of MGb2-Ag/TRAK1 expression as a prognostic indicator was also evaluated.
  
  
  METHODS
  Immunohistochemistry and western blot were used to detect MGb2-Ag/TRAK1 expression in 140 CRC tissues. The relationship between MGb2-Ag/TRAK1 expression and clinicopathological characteristics and postoperative survival time was statistically analyzed.
  
  
  RESULTS
  MGb2-Ag/TRAK1 expression in CRC tissues was significantly higher than in normal tissues and was positively correlated with tumor differentiation (p = 0.006), invasion (p = 0.049), and pathological stage (p = 0.032). There was no significant difference between MGb2-Ag/TRAK1 expression and the age or gender of the patient, lymphatic invasion, or distant metastasis (p = 0.586, 0.308, 0.910, and 0.068, respectively). The survival time of CRC patients with high expression of MGb2-Ag/TRAK1 was shorter than the survival time of patients with low MGb2-Ag/TRAK1 expression. Both univariate and multivariate analyses showed that tumor differentiation and MGb2-Ag/TRAK1 expression were two independent and prognostic factors for CRC (p < 0.001).
  
  
  CONCLUSIONS
  MGb2-Ag/TRAK1 may play an important role in the development of CRC and may be a valuable prognostic indicator of CRC.
authors.affiliation: State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Changle Western Road, 169, Xi'an, Shaanxi Province, 710032, China.
authors.forename: Yanxin
authors.initials: Y
authors.lastname: An
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Gui
authors.initials: G
authors.lastname: Ren
authors.forename: Qifei
authors.initials: Q
authors.lastname: Tian
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Lu
authors.forename: Hongtao
authors.initials: H
authors.lastname: Li
authors.forename: Kai
authors.initials: K
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Su
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Shuo
authors.initials: S
authors.lastname: Chen
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Xipeng
authors.initials: X
authors.lastname: Zhang
authors.forename: Yongzhan
authors.initials: Y
authors.lastname: Nie
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Qingchuan
authors.initials: Q
authors.lastname: Zhao
mesh_terms: D033942:Adaptor Proteins, Vesicular Transport / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D021381:Protein Transport; D013347:Subcellular Fractions / Q000378:metabolism; D055815:Young Adult
chemical_list: D033942:Adaptor Proteins, Vesicular Transport; C531552:TRAK1 protein, human